Cargando…

Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population

BACKGROUND: Canagliflozin is the first sodium-glucose co-transporter-2 (SGLT-2) inhibitor—a new class of oral antidiabetic (OAD) medication— approved for type 2 diabetes mellitus (T2DM) treatment in the United States. Approved less than 2 years ago, use of canagliflozin is largely uncharacterized. O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michael, Grabner, Xiaomei, Peng, Geremakis, Caroline, Bae, Jay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398281/ https://www.ncbi.nlm.nih.gov/pubmed/26679969 http://dx.doi.org/10.18553/jmcp.2015.21.12.1204

Ejemplares similares

Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States
por: Kalirai, Samaneh, et al.
Publicado: (2020)

A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus
por: Nardolillo, AnneMarie, et al.
Publicado: (2014)

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
por: Woo, Vincent, et al.
Publicado: (2018)

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
por: Triplitt, Curtis, et al.
Publicado: (2015)

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
por: Shubrook, Jay, et al.
Publicado: (2011)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
por: Bays, Harold E, et al.
Publicado: (2014)

Retrospective Analysis of Long-Term Adherence to and Persistence with DPP-4 Inhibitors in US Adults with Type 2 Diabetes Mellitus
por: Farr, Amanda M., et al.
Publicado: (2014)

Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS)
por: Hassanein, Mohamed, et al.
Publicado: (2017)

Survey of Premium Versus Large Manufactured Cigars Use in U.S. Consumers
por: Smith, Carson, et al.
Publicado: (2023)

Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
por: Yagi, Shusuke, et al.
Publicado: (2017)

Demographic and Geographic Differences in Exposure to Secondhand Smoke in Missouri Workplaces, 2007-2008
por: Harris, Jenine K., et al.
Publicado: (2011)

Demographic and lifestyle factors and selenium levels in men and women in the U.S.
por: Park, Kyong, et al.
Publicado: (2011)

Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program
por: Matthews, David R., et al.
Publicado: (2020)

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
por: Iijima, Hiroaki, et al.
Publicado: (2015)

Management of diabetes mellitus in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon
por: Sehgal, Vishal, et al.
Publicado: (2014)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India
por: Prasanna Kumar, K. M., et al.
Publicado: (2016)

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus
por: Davies, M. J., et al.
Publicado: (2015)

Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
por: Budoff, Matthew J., et al.
Publicado: (2017)

Canagliflozin – Beginning of the journey
por: Pandey, Sunil Kumar, et al.
Publicado: (2014)

DPP-4 Inhibitors Improve Liver Dysfunction in Type 2 Diabetes Mellitus
por: Kanazawa, Ippei, et al.
Publicado: (2014)

U.S. Large Hadron Collider (U.S. LHC) construction: project execution plan (PEP)
por: Yeck, James H, et al.
Publicado: (2002)

Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?
por: Tanaka, Atsushi, et al.
Publicado: (2017)

DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?
por: Bae, Ji Cheol
Publicado: (2022)

Cardiovascular outcomes and mortality after initiation of canagliflozin: Analyses from the EASEL Study
por: Udell, Jacob A., et al.
Publicado: (2019)

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
por: Weir, Matthew R, et al.
Publicado: (2020)

Evolution of Depression and Anxiety During the COVID-19 Pandemic and Across Demographic Groups in a Large Sample of U.S. Adults
por: Ettman, Catherine K., et al.
Publicado: (2023)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates
por: John, Mathew, et al.
Publicado: (2016)

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
por: Rådholm, Karin, et al.
Publicado: (2018)

Effects of canagliflozin on cardiac remodeling and hemodynamic parameters in patients with type 2 diabetes mellitus
por: Kuo, Hsiao-Huai, et al.
Publicado: (2023)

Missed opportunities for human papillomavirus vaccine series initiation in a large, rural U.S. state
por: Newcomer, Sophia R., et al.
Publicado: (2022)

Crystal structure of canagliflozin hemihydrate
por: Liu, Kai-Hang, et al.
Publicado: (2016)

Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy
por: Kutoh, Eiji, et al.
Publicado: (2017)

Demographic determinants of syphilis seroprevalence among U.S. blood donors, 2011–2012
por: Kane, Mark Andrew, et al.
Publicado: (2015)

Dimensions of Thermal Inequity: Neighborhood Social Demographics and Urban Heat in the Southwestern U.S.
por: Dialesandro, John, et al.
Publicado: (2021)

Future Temperature‐Related Deaths in the U.S.: The Impact of Climate Change, Demographics, and Adaptation
por: Lee, Jangho, et al.
Publicado: (2023)

U.S. participates in Large Hadron Collider project
Publicado: (2008)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
por: Liu, Jinglong, et al.
Publicado: (2014)

The initial effect of U.S. tax reform on foreign acquisitions
por: Amberger, Harald J., et al.
Publicado: (2023)

Clinical, demographic and laboratory parameters at HAART initiation associated with decreased post-HAART survival in a U.S. military prospective HIV cohort
por: Lifson, Alan R, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2pnloh7qqjnje9knf10ejg0789